Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the launch of a powerful new capability at Ginkgo Datapoints: high-throughput, low-cost ADME (Absorption, Distribution, Metabolism, and Excretion) profiling, enabled by Ginkgo's proprietary RAC automation. This new service aims to beat or match the price of Chinese or other international vendors, with all work performed in the United States.
This cutting-edge ADME service is designed to dramatically accelerate and help to de-risk the drug development pipeline for small molecules and is optimized for machine learning applications. By providing early access to rich ADME data, Ginkgo Datapoints aims to empower researchers to prioritize candidates and train predictive models with unprecedented speed and efficiency. This offering reinforces Ginkgo's commitment to providing top-tier, cost-effective services to the biopharma industry.
"We are thrilled to launch our new ADME service, which we believe will be a game-changer for drug discovery," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "We will price match any ADME service quote you get (including from Chinese or other international vendors), though we hope to beat them on per-compound pricing out of the gate anyway. We believe our automation and scale at Ginkgo allow us to offer best-in-class pricing and quality."
Key features of the new ADME profiling service include:
• Scalable, automated workflows—the Ginkgo standard
• Cost-effective pricing built for throughput, with a price match guarantee against international vendors
• Rapid turnaround to keep pace with modern discovery cycles
• Model-ready datasets, enriched with structured metadata for AI-powered insights
This is biology built for algorithms. No more fragmented data. No more delays. Just fast, clean, AI-compatible outputs delivered at library scale.
